Access Biotechnology
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- USA
- United Kingdom
Investment stages
- Pre-Seed
- Seed
- Series A
- Series B
Industries
- Biotech
- Health Tech
- Artificial Intelligence
About
Access Biotechnology, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to latestage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.
Access Biotechnology, a segment of Access Industries, was founded in 2019 and is led by Liam Ratcliffe, former head of worldwide clinical R&D at Pfizer. They focus on investing in both private and public biopharma companies at various development stages, from discovery to latestage clinical programs. Their approach emphasizes longterm orientation, adaptability, technical rigor, and collaboration. They have a portfolio of over 30 investments, with more than 5 exits. Notable investments include Disc Medicine, Eliem Therapeutics, Day One Biopharmaceuticals, Perfuse Therapeutics, Nimbus Therapeutics, and many others.
Investment Thesis
Access Biotechnology invests in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health.
Team
Alan Au (Partner)
Mary Kerr (Partner)
John Burke (Partner)
Portfolio
Disc Medicine
Eliem Therapeutics
Day One Biopharmaceuticals
Perfuse Therapeutics
Nimbus Therapeutics
Recludix Pharma
Halda Therapeutics
Upstream Bio
Areteia Therapeutics
Acelyrin
Matchpoint Therapeutics
Hemab Therapeutics
Zura Bio
Vyne Therapeutics
Apogee Therapeutics
Spyre Therapeutics
Santa Ana Bio
GRO Biosciences